GlassScriptPhysician profile
Carly Barth
NPI 1588926604
$1,178.60
in general payments reported to CMS, 2019-2025
14 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $15.83 · 2023: $166 · 2024: $245 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.38 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.01 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $186.24 | 2025 | Omvoh |
| Genzyme Corporation | $77.12 | 2023-2024 | |
| Braintree Laboratories, INC. | $47.81 | 2019 | |
| Ferring Pharmaceuticals INC. | $44.43 | 2019 | |
| Allergan, INC. | $37.28 | 2019 | |
| Pfizer INC. | $36.16 | 2024-2025 | |
| Celgene Corporation | $35.31 | 2023-2024 | Zeposia |
| Novo Nordisk INC | $26.47 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2019 | |
| Evoke Pharma, INC. | $17.53 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.34 | 2023 | Voquezna |
| Ironwood Pharmaceuticals, INC | $15.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Barth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.